Somatic mutation counts as a surrogate marker for tumor mutation burden to predict progesterone receptor-positive (PR+) status in PIK3CA-mutated breast cancer
GMS German Medical Science · 20.11.2025 · 23 (Doc16) · Doc16
DOI: 10.3205/000352 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift GMS German Medical Science, erschienen am 20.11.2025. Verfasst von Bandana Kumari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, All India Institute of Medical Sciences, Patna, Bihar, India. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Receptors, Progesterone, Biomarkers, Tumor. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Invasive ductal carcinoma (IDC), the most prevalent subtype of breast cancer, is characterized by significant genomic heterogeneity. Tumor mutation burden (TMB) has emerged as a predictive biomarker for immunotherapy response, yet its estimation via whole-exome sequencing remains complex and costly. This study aimed to evaluate whether total somatic mutation count can serve as a practical surrogate for TMB and assess its association with progesterone receptor (PR) status in PIK3CA-mutated IDC patients.
Methods
This retrospective observational study utilized publicly available data from a previously published breast cancer sequencing study. A total of 164 female IDC patients with confirmed PIK3CA mutations and documented PR status were included. Relevant genomic and demographic parameters – TMB, mutation count, and age – were extracted and analyzed. Statistical analyses included correlation, intergroup comparisons by PR status, and binary logistic regression. Predictive performance was assessed using area under the receiver operating characteristic (AUROC) curves.
Results
Patients with PR-negative status exhibited significantly higher TMB and mutation count than PR-positive patients (p-value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, All India Institute of Medical Sciences, Patna, Bihar, India.
- All India Institute of Medical Sciences, Patna, Bihar, India.
Zitieren
APA
Kumari, B., & Lahariya, R. (2025). Somatic mutation counts as a surrogate marker for tumor mutation burden to predict progesterone receptor-positive (PR+) status in PIK3CA-mutated breast cancer. GMS German Medical Science, 23(Doc16), Doc16. https://doi.org/10.3205/000352
Vancouver
Kumari B, Lahariya R. Somatic mutation counts as a surrogate marker for tumor mutation burden to predict progesterone receptor-positive (PR+) status in PIK3CA-mutated breast cancer. GMS German Medical Science. 2025;23(Doc16):Doc16. doi:10.3205/000352
BibTeX
@article{Kumari2025,
author = {Kumari, Bandana and Lahariya, Rijhul},
title = {Somatic mutation counts as a surrogate marker for tumor mutation burden to predict progesterone receptor-positive (PR+) status in PIK3CA-mutated breast cancer},
journal = {GMS German Medical Science},
year = {2025},
volume = {23},
number = {Doc16},
pages = {Doc16},
doi = {10.3205/000352}
}
EUVIMED